Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Compelling evidence supports a causal role for lipoprotein (a)(Lp (a)) in cardiovascular
disease. No pharmacotherapies directly targeting Lp (a) are currently available for clinical …

OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …

Owing to specific and compelling gene silencing, RNA interference (RNAi) is expected to
become an essential approach in treating a variety of infectious, hemato-oncological …

version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …

Background There remains uncertainty about the impact of menopausal hormone therapy
(MHT) on women's health. A systematic, comprehensive assessment of the effects on …

Background Findings of historical studies suggest that elevated LDL cholesterol is not
associated with increased risk of myocardial infarction and atherosclerotic cardiovascular …